Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis

ADVERTISEMENT RETURN TO ISSUEPREVPatent HighlightNEXTEmopamil-Binding Protein Inhibitors for Treating Multiple SclerosisRam W. Sabnis*Ram W. SabnisSmith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States*E-mail: [email protected]More by Ram W. Sabnishttps://orcid.org/0000-0001-7289-0581Cite this: ACS Med. Chem. Lett. 2023, 14, 10, 1318–1319Publication Date (Web):September 6, 2023Publication History Received19 August 2023Published online6 September 2023Published inissue 12 October 2023https://doi.org/10.1021/acsmedchemlett.3c00366Copyright © Published 2023 by American Chemical SocietyRequest reuse permissions This publication is free to access through this site. Learn MoreArticle Views701Altmetric-Citations-LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InReddit PDF (949 KB) Get e-AlertscloseSUBJECTS:Alkyls,Inhibition,Inhibitors,Pharmaceuticals,Steroids Get e-Alerts